Replies to post #175423 on Cytodyn Inc (CYDY)

[daemon57]

This is some very good analysis. Thanks (I didn't have time to look throug all slides, values). I did find this:

https://www.nejm.org/doi/full/10.1056/NEJMoa2028485


"A total of 468 patients without brain metastases were randomly assigned to receive sacituzumab govitecan (235 patients) or chemotherapy (233 patients). "

I didn't fully look through their exclusion criteria (as we had none) but if I were to take a bet -- LL with that number of patients and power would clearly lead the pack and become SOC. All, IMHO.

*edit - SAE for Trodelvy: neurtropina and s. diarhea.. Last I checked, LL has no SAE's. Trodevly also given by IV weekly. LL (someone correct me if I'm wrong here) would be subQ.

GLTU/A.

[HouseofCards]

Any idea on the safety profile between LL and SG? I know LL hasn't shown any SAEs but did SG?

[Learning53]

Appreciate the information and analysis! Thank you for taking the time to write-up and present an excellent (IMO) summary!